Nanochon, an orthopedic device company, closed a $4.1 million Seed Prime II funding round.
The company is developing an implant for treating cartilage defects in the knee. The funding will be used for its first in-human clinical study for the implant, according to a Jan. 12 cultivate(MD), which led the funding round.
The phase 1 trial will evaluate the efficacy and safety of the company’s Chondrograft knee implant in a 10 patient study.
In total, Nanochon has raised $11.3 million in capital, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.